Giving the high failure rate of drug candidates in clinical trials – in particular involving the central nervous system (lack of efficacy or neurotoxicity), we aim at developing more relevant and more predictive brain in vitro models for preclinical in vitro assessment. For that, we are recreate cerebral in vitro models in 3 dimensions, including the microenvironment using our technology BIOMIMESYS®.
What we bring to the partnership
We are developing relevant cerebral in vitro models, including:
- Several cerebral cell types, in particular neurons and glial cells, to take into account cell-cell interaction, for example to study neuro-inflammation
- A chemical defined media, for a good reproducibility
- A 3-dimensional organization, to better mimic cerebral tissue structure
- The matricial microenvironment thanks to our technology BIOMIMESYS® Brain, a functionalized hyaluronic acid-based hydroscaffold which mimics the brain extracellular matrix.
These models are available in 96- and 384-well formas, compatible with our robotic platform for High Content Screening.
List of partners
- Inserm Unit 1171
- HCS pharma
List of related articles
- Our new article: In vitro differentiation modifies the neurotoxic response of SH-SY5Y cells
- Microglia and Astrocytes in Parkinson’s Disease Neuroinflammation
- Poster – Importance of matricial and cellular microenvironments in in vitro models for drug discovery in Parkinson’s disease
- We will present our researches on the importance of ECM for drug discovery in Parkinson’s disease at NeuroFrance congress (May 19 to 21 )
- The central nervous system in drug discovery